Opioid use disorder

Last updated: September 09, 2025

Opioid use disorder

Watch later

Watch later

Human herpesvirus 8 (Kaposi sarcoma)
Herpes simplex virus
Human herpesvirus 6 (Roseola)
Adenovirus
Parvovirus B19
Human papillomavirus
BK virus (Hemorrhagic cystitis)
JC virus (Progressive multifocal leukoencephalopathy)
Poliovirus
Coxsackievirus
Rhinovirus
Hepatitis A and Hepatitis E virus
Influenza virus
Mumps virus
Measles virus
Respiratory syncytial virus
Human parainfluenza viruses
Yellow fever virus
Zika virus
Hepatitis C virus
West Nile virus
Norovirus
Rotavirus
HIV (AIDS)
Rabies virus
Rubella virus
Prions (Spongiform encephalopathy)
Candida
Plasmodium species (Malaria)
Trypanosoma cruzi (Chagas disease)
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Mechanisms of antibiotic resistance
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Nuclear structure
DNA structure
Transcription of DNA
Translation of mRNA
Gene regulation
Epigenetics
Amino acids and protein folding
Nucleotide metabolism
DNA replication
Lac operon
DNA damage and repair
Cell cycle
Mitosis and meiosis
DNA mutations
Lesch-Nyhan syndrome
Adenosine deaminase deficiency
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
Gel electrophoresis and genetic testing
ELISA (Enzyme-linked immunosorbent assay)
Karyotyping
DNA cloning
Fluorescence in situ hybridization
Mendelian genetics and punnett squares
Hardy-Weinberg equilibrium
Inheritance patterns
Independent assortment of genes and linkage
Evolution and natural selection
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Fragile X syndrome
Huntington disease
Myotonic dystrophy
Friedreich ataxia
Turner syndrome
Klinefelter syndrome
Prader-Willi syndrome
Angelman syndrome
Cri du chat syndrome
Williams syndrome
Alagille syndrome (NORD)
Achondroplasia
Polycystic kidney disease
Familial adenomatous polyposis
Familial hypercholesterolemia
Marfan syndrome
Multiple endocrine neoplasia
Neurofibromatosis
Tuberous sclerosis
von Hippel-Lindau disease
Albinism
Cystic fibrosis
Gaucher disease (NORD)
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Hemochromatosis
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Leukodystrophy
Niemann-Pick disease types A and B (NORD)
Niemann-Pick disease type C
Phenylketonuria (NORD)
Sickle cell disease (NORD)
Tay-Sachs disease (NORD)
Alpha-thalassemia
Beta-thalassemia
Wilson disease
Alport syndrome
X-linked agammaglobulinemia
Fabry disease (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hemophilia
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Muscular dystrophy
Wiskott-Aldrich syndrome
Mitochondrial myopathy
Autosomal trisomies: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Miscellaneous genetic disorders: Pathology review
Human development days 1-4
Human development days 4-7
Human development week 2
Human development week 3
Ectoderm
Mesoderm
Endoderm
Development of the placenta
Development of the fetal membranes
Development of twins
Hedgehog signaling pathway
Development of the digestive system and body cavities
Development of the umbilical cord
Development of the cardiovascular system
Fetal circulation
Development of the face and palate
Pharyngeal arches, pouches, and clefts
Development of the gastrointestinal system
Development of the teeth
Development of the tongue
Development of the axial skeleton
Development of the muscular system
Development of the renal system
Development of the reproductive system
Development of the respiratory system
Cellular structure and function
Cell membrane
Selective permeability of the cell membrane
Extracellular matrix
Cell-cell junctions
Endocytosis and exocytosis
Osmosis
Resting membrane potential
Nernst equation
Cytoskeleton and intracellular motility
Cell signaling pathways
Adrenoleukodystrophy (NORD)
Zellweger spectrum disorders (NORD)
Ehlers-Danlos syndrome
Peroxisomal disorders: Pathology review
Introduction to biostatistics
Types of data
Probability
Mean, median, and mode
Range, variance, and standard deviation
Standard error of the mean (Central limit theorem)
Normal distribution and z-scores
Paired t-test
Two-sample t-test
Hypothesis testing: One-tailed and two-tailed tests
One-way ANOVA
Two-way ANOVA
Repeated measures ANOVA
Correlation
Methods of regression analysis
Linear regression
Logistic regression
Type I and type II errors
Sensitivity and specificity
Positive and negative predictive value
Test precision and accuracy
Incidence and prevalence
Relative and absolute risk
Odds ratio
Mortality rates and case-fatality
DALY and QALY
Direct standardization
Indirect standardization
Study designs
Ecologic study
Cross sectional study
Case-control study
Cohort study
Randomized control trial
Clinical trials
Sample size
Disease causality
Selection bias
Information bias
Confounding
Interaction
Prevention
Major depressive disorder
Suicide
Bipolar and related disorders
Major depressive disorder with seasonal pattern
Generalized anxiety disorder
Social anxiety disorder
Panic disorder
Phobias
Obsessive-compulsive disorder
Body focused repetitive disorders
Post-traumatic stress disorder
Schizophrenia
Delirium
Amnesia
Dissociative disorders
Anorexia nervosa
Bulimia nervosa
Cluster A personality disorders
Cluster B personality disorders
Cluster C personality disorders
Somatic symptom disorder
Factitious disorder
Tobacco use disorder
Opioid use disorder
Cannabis use disorder
Cocaine use disorder
Alcohol use disorder
Bruxism
Insomnia
Narcolepsy (NORD)
Erectile dysfunction
Attention deficit hyperactivity disorder
Disruptive, impulse control, and conduct disorders
Learning disability
Fetal alcohol syndrome
Tourette syndrome
Autism spectrum disorder
Rett syndrome
Mood disorders: Pathology review
Amnesia, dissociative disorders and delirium: Pathology review
Personality disorders: Pathology review
Eating disorders: Pathology review
Psychological sleep disorders: Pathology review
Psychiatric emergencies: Pathology review
Drug misuse, intoxication and withdrawal: Hallucinogens: Pathology review
Malingering, factitious disorders and somatoform disorders: Pathology review
Trauma- and stress-related disorders: Pathology review
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Atypical antidepressants
Typical antipsychotics
Atypical antipsychotics
Lithium
Nonbenzodiazepine anticonvulsants
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants

Transcript

Watch video only

Worldwide, opioids are the most common cause of drug-related deaths.
The number of individuals using opioids has drastically increased over time, with an uptick in heroin use, and an even bigger uptick in prescription opioid use, and a large number of people using both. Because of the potential for opioid use disorder and overdose, opioids are regulated substances in many countries.

As a class, opioids share one thing in common—they bind to opioid receptors in the brain, spinal cord, and gastrointestinal tract. Some are endogenous, meaning that they are produced naturally by the body, like endorphins, which are named for “endogenous morphine” due to their similar effects on the body. But others are exogenous, meaning that they come from outside the body, like heroin and morphine, which come from the opium poppy—a flowering plant that oozes a milky white liquid—while others like fentanyl are synthesized in the laboratory.

To understand how opioids work, let’s zoom in on a region of the spinal cord that has opioid receptors. Normally, in the absence of endorphins, nociceptive fibers carry pain signals from the body to the dorsal, or posterior, horn of the spinal cord.

Here they release neurotransmitters,

like glutamate, substance P and calcitonin gene-related peptide. These neurotransmitters cause pain signals to be transmitted to the brain via ascending pain pathways.

Now, let’s say someone goes to play a rigorous game of badminton. Exercise releases endorphins which activate the three major opioid receptors located on neurons, called the mu, kappa, and delta receptors.

As endorphins or other opioids bind to these receptors on the presynaptic terminals of nociceptive fibers, they inhibit the opening of calcium channels, preventing calcium influx, and thereby blocking the release of pain-causing neurotransmitters like glutamate, substance P and calcitonin gene-related peptide. At the same time, endorphins also bind to postsynaptic neurons, opening potassium channels here, leading to hyperpolarization and decreased excitability of the neuron. These effects together reduce the transmission of pain signals to the brain.

If we move up to the brain’s reward pathway, made up of midbrain regions like the ventral tegmental area, nucleus accumbens, and prefrontal cortex, we find another important effect of opioids.

Here, inhibitory neurons normally release gamma-aminobutyric acid, or GABA, at the presynaptic terminal, which in turn inhibits postsynaptic dopaminergic neurons, leading to decreased dopamine release.

But, when there are endorphins or opioids in the area, they bind to the opioid receptors on these inhibitory GABAergic neurons, causing a decrease in GABA release. With less GABA around, there is less inhibition of dopaminergic neurons, leading to a flood of dopamine in the brain’s reward center. This increased dopamine leads to a calming sensation and feelings of pleasure or euphoria, also known as an emotional “high”.

Now remember, the purpose of the reward pathway is to train the brain to repeat activities that cause dopamine-mediated pleasure, so when opioids stimulate this reward pathway, the brain learns to do that behavior again and again.

With exogenous opioids, there are multiple routes to get the drug to the brain.

One way is by ingesting it; that route is the slowest. A faster route would be inhalation because the drug is rapidly absorbed through the lungs; this route is not routinely used medically and is more commonly encountered with substance misuse.

The fastest route is direct injection of the substance into the blood. Typically, the faster the exogenous opioid reaches the brain, the stronger the relationship between the behavior and the reward.

Over time, people can develop tolerance to a drug. Tolerance means that with repeated use, their response to the drug decreases. As a result, even when taking the medication exactly as prescribed, a higher dose may be needed to achieve the same effect as before.

At a cellular level, there are two main reasons for why this happens.

One reason is that opioid receptors become less sensitive to stimulation by a drug, and the other reason is that the neurons may remove opioid receptors from the cell membrane in a process called down-regulation, leaving fewer receptors available for binding. In either scenario, tolerance leads to the need for higher and higher doses of a drug, and often that tolerance remains for a long time even after tapering off the drug.

Alright, so now let’s say that you’re at rest, there aren’t any drugs or anything else stimulating your reward pathway. In this situation, your brain keeps your heart rate, blood pressure, and wakefulness in a normal state, called homeostasis.

Now, let’s say you finally get a text with exam results that you’ve been waiting weeks for. All of a sudden you may feel sweaty and flushed, your heart rate may jump a bit. You’re now above your normal level of homeostasis, because something has changed, right? But it doesn’t stay that way for long, and after the text message, your brain brings things back down to this baseline.

With repeated drug use, a few things start to happen.
Let’s say you take a drug at a specific time and setting, like 3:00 P.M. in the bedroom, every day.

If it’s a depressant, it makes everything go lower: heart rate, blood pressure, and wakefulness.

Your brain, being the smart brain that it is, will pick up on this pattern.

So, the next time it’s 3:00 P.M. in the bedroom, your brain preemptively increases heart rate, blood pressure and wakefulness, since it knows that when you take the drug, everything’s going to decrease again.

Now, let’s say 3:00 P.M. in the bedroom rolls around, but there’s no drug…

In that situation, the brain still increases everything, but the changes aren’t countered with the effects of the drug, and so the person can feel awful;

these are called withdrawal symptoms. These symptoms can persist to the point where a person may need drugs just to feel normal, and if that’s the case, they are considered to be dependent on that drug.

Now, on the flipside, let’s say that you use the drug in an unfamiliar setting, like at 11:00 P.M. at a party. Well in that situation, your body’s not ready for the drug and there’s no physiologic “counterbalance” to help offset the effect of the drug.

When that happens, it can lead to overdose, even on a “normal” dose that the person’s taking, and that’s oftentimes what happens.

The symptoms of opioid withdrawal include dysphoric mood, myalgias, sweating and shivering, yawning, nausea, vomiting, and diarrhea, rhinorrhea, pupillary dilation, and insomnia.

These symptoms can feel really awful, and often prompt people to use opioids again. This is called negative reinforcement, since you’re removing the drug, which causes withdrawal symptoms which reinforces more drug use to avoid those symptoms.

Key Takeaways

An opioid use disorder is a medical condition that is characterized by the compulsive use of opioids in spite of adverse consequences from continued use and the development of a withdrawal syndrome when opioid use stops. Opioids include substances such as morphine, heroin, codeine, oxycodone, hydrocodone, etc. The necessary descriptive characteristics of the medical diagnosis are preoccupation with a desire to obtain and take the drug and persistent drug-seeking behaviour. 

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine" McGraw Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "Pharmacological therapies for management of opium withdrawal" Cochrane Database of Systematic Reviews (2018)
  5. "An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program" Drug and Alcohol Dependence (2011)
  6. "Cellular basis of memory for addiction" Dialogues in Clinical Neuroscience (2013)